META vs SIFY

META exhibits exceptional fundamental health with a Piotroski F-Score of 8/9, indicating strong financial strength across profitability, leverage, and operating efficiency. While the current price of $612.42 trades at a premium to the Graham Number ($213.17) and the growth-based Intrinsic Value ($542.14), the PEG ratio of 0.94 suggests the stock is undervalued relative to its high growth rate. Strong revenue growth (23.8%) and a low forward P/E (17.03) outweigh the bearish technical trend and insider selling. The company's dominant market position and consistent earnings beats support a bullish long-term outlook.

SIFY exhibits severe financial distress as evidenced by a critical Piotroski F-Score of 1/9, indicating a near-total failure of fundamental health metrics. While revenue growth remains strong at 24% YoY, this is completely offset by a catastrophic YoY EPS decline of 107.7% and a negative profit margin. The valuation is disconnected from reality, with a Forward P/E of 268.40 and a PEG ratio of 34.30, suggesting the stock is priced for perfection despite deteriorating earnings. The recent 1-year price surge appears speculative and is not supported by the underlying deterministic health or value scores.